

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model

Robin Q.H. Kloos,¹ Ron Mathôt,² Rob Pieters³ and Inge M. van der Sluis^{1,3}

¹Department of Pediatric Oncology and Hematology, Sophia Children's Hospital – Erasmus MC, Rotterdam; ²Department of Hospital Pharmacy, Amsterdam University Medical Center, University of Amsterdam, Amsterdam and ³Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Correspondence: I.M. van der Sluis
i.m.vandersluis@prinsesmaximacentrum.nl


Received: June 5, 2023.

Accepted: June 5, 2023.

Early view: June 15, 2023.

<https://doi.org/10.3324/haematol.2023.283685>

©2023 Ferrata Storti Foundation

Published under a CC-BY-NC license 

With reference to our paper published in the May issue 2021 of *Haematologica*,¹ we would like to draw your attention to Table 5 which contains two typing errors. In fact, in the column “Target trough levels: 100-250 IU/L”, the second “Week level” range should be 100-150 IU/L instead of 100-250 IU/L, while in the column “Target trough levels: 250-400 IU/L” the third “Week level” range should be 300-350 IU/L instead of 300-250 IU/L, as shown in the corrected Table 5 below.

Corrected Table 5. Dosing guideline, dose adjustments.

Target trough level: 100-250 IU/L			Target trough level: 250-400 IU/L		
Week level	Trough level	Dose adjustment	Week level	Trough level	Dose adjustment
50-100 IU/L	25-50 IU/L	400%	100-200 IU/L	50-100 IU/L	400%
100-150 IU/L	50-75 IU/L	300%	200-300 IU/L	100-150 IU/L	300%
150-200 IU/L	75-100 IU/L	200%	300-350 IU/L	150-200 IU/L	200%
200-450 IU/L	100-250 IU/L	100%	350-450 IU/L	200-250 IU/L	175%
450-550 IU/L	250-300 IU/L	60%	450-700 IU/L	250-400 IU/L	100%
550-750 IU/L	300-400 IU/L	50%	700-900 IU/L	400-500 IU/L	70%
750-1100 IU/L	400-600 IU/L	40%	900-1100 IU/L	500-600 IU/L	60%
1100-1500 IU/L	600-800 IU/L	25%	1100-1250 IU/L	600-700 IU/L	50%
1500-1800 IU/L	800-1000 IU/L	20%	1250-1800 IU/L	700-1000 IU/L	35%

The dose adjustments apply for biweekly administration of PEGasparaginase during steady state. The doses may be adjusted based on week (7 days) or trough (14 days) after administration targeting at trough asparaginase activity levels of 100-250 IU/L or 250-400 IU/L.

References

1. Kloos RQH, Mathôt R, Pieters R, van der Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing

the clearance: a population pharmacokinetic model. *Haematologica*. 2021;106(5):1254-1261.